Patheon Inc. Expands Toronto Facility, Creates Dedicated Space for Oral Contraceptives Production

    RESEARCH TRIANGLE PARK, NC, April 17 /CNW/ - Patheon Inc. (TSX: PTI), a
global provider of drug development and manufacturing services to the
international pharmaceutical industry, is pleased to announce the expansion of
its Toronto manufacturing facility. The expansion adds 10,000 square feet of
GMP space dedicated to the production of oral contraceptives with a potential
output of 1.3 billion tablets. This includes full-scale commercial production
capabilities, including dispensing, granulation, compression, film coating and
primary packaging. The new area will utilize abatement technology, which is
used for the elimination of solvent emissions and meets projected 2020
Ministry of Environment Standards.
    The expansion of dedicated space for the production of oral
contraceptives, is a regulatory requirement to sell in many countries, and
demonstrates Patheon's continuing commitment to providing the highest level of
quality and standards to customers. By providing dedicated space, Patheon will
free up manufacturing capacity in the Toronto facility for current and new
commercial business and allow for future growth within the Pharmaceutical
Development Services area. The newly expanded Toronto site will be a Center of
Excellence for Oral Contraceptives under Patheon's proprietary Quick to
Clinic(TM) program.
    Terry Novak, President of North America stated, "This expansion positions
Patheon to compete on a higher level for contract manufacturing opportunities
and claim a larger portion of the global oral contraceptive manufacturing


    Patheon Inc. (TSX: PTI; is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.

    Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at or on SEDAR at

    %SEDAR: 00001700E

For further information:

For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email:; Mr. Eric Evans,
Chief Financial Officer, Tel: (919) 226-3200, Email:;
Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email:

Organization Profile

Patheon Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890